# T-Therapeutics Closes Oversubscribed $133 Million Series B Co-Led by Advent and British Business Bank

> T-Therapeutics closed an oversubscribed $133 million Series B co-led by Advent Life Sciences and British Business Bank to fund two TCR-CD3 bispecific programmes.

- Published: 2026-11-05T07:24:47+00:00
- Section: Funding
- Author: News Desk
- URL: https://newsforagent.com/news/2026-11-05/t-therapeutics-series-b-financing
- Source: [GlobeNewswire](https://www.globenewswire.com/news-release/2026/11/05/3396064/0/en/t-therapeutics-announces-oversubscribed-133-million-series-b-financing-to-achieve-clinical-proof-of-concept-for-first-in-class-tcr-bispecific-therapies-in-cancer-and-autoimmune-dis.html)

## Key takeaways

- T-Therapeutics closed an oversubscribed $133 million Series B co-led by Advent Life Sciences and British Business Bank.
- Proceeds will fund two first-in-class TCR-CD3 bispecific programmes in cancer and autoimmune disease through clinical proof-of-concept.
- Dr. Kirsty Crame joined T-Therapeutics as Chief Development Officer alongside the financing.

T-Therapeutics closed an oversubscribed $133 million Series B financing co-led by Advent Life Sciences and British Business Bank to fund two first-in-class TCR-CD3 bispecific programmes through clinical proof-of-concept. The Cambridge, UK biotechnology company announced the close on November 5, 2026, according to [GlobeNewswire](https://www.globenewswire.com/news-release/2026/11/05/3396064/0/en/t-therapeutics-announces-oversubscribed-133-million-series-b-financing-to-achieve-clinical-proof-of-concept-for-first-in-class-tcr-bispecific-therapies-in-cancer-and-autoimmune-dis.html).

## T-Therapeutics' Series B Investors and Proceeds

New investors in the round include Johnson & Johnson Innovation – JJDC, Inc. (JJDC), Samsara BioCapital, M-Ventures and [Eli Lilly](https://akta.pro/company-profiles/00000ap/eli-lilly) and Company (Lilly), alongside all existing major shareholders: Sofinnova Partners, F-Prime, Digitalis Ventures, Cambridge Innovation Capital, Sanofi Ventures, Tencent and BGF. Representatives from Advent Life Sciences, British Business Bank, JJDC and Samsara BioCapital will join the board of [T-Therapeutics](https://akta.pro/company-profiles/0000u3l/t-therapeutics) as non-executive directors.

The proceeds will support entry into the clinic and the generation of clinical proof-of-concept data for the two lead programmes, which use the company's OpTiMus platform for fully human TCRs against intracellular targets. The oncology programme targets solid tumours, while the immunology programme aims at selective depletion of pathogenic cells driving chronic tissue inflammation.

Theodora Harold, Chief Executive Officer of T-Therapeutics, said: "This financing is a key step in our transition to a clinical-stage company, enabling us to accelerate the development of two oncology and immunology programmes with pan-indication, blockbuster potential, underpinned by a platform that reaches targets long considered undruggable."

Dominic Schmidt, General Partner at [Advent Life Sciences](https://akta.pro/company-profiles/0003lzx/advent-life-sciences), said T cell engagers have delivered clinical success in haematological cancers but have been held back in solid tumours by the lack of appropriate targets. In September 2026, the British Business Bank committed £60m to Advent Life Sciences Fund IV and £75m to Advent Life Sciences Growth Fund, totaling £135m, Investorsinhealthcare reported.

## T-Therapeutics' Earlier Funding Rounds

According to akta.pro [company records](https://akta.pro/company-data), T-Therapeutics raised a $59.6 million Series A in November 2023 led by Cambridge Innovation Capital, Digitalis Ventures and F-Prime, and a $32 million Series A extension in November 2025 with new investors Tencent and BGF, bringing the Series A total to $91 million.

| Round | Date | Amount |
| --- | --- | --- |
| Series A | November 2023 | $59.6 million |
| Series A extension | November 2025 | $32 million |
| Series A total | — | $91 million |

## Kirsty Crame's Chief Development Officer Role

Alongside the financing, T-Therapeutics appointed Dr. Kirsty Crame as Chief Development Officer to oversee translational and clinical development of its pipeline. Dr. Crame previously served as Chief Medical Officer at Curatis AG and led early-stage clinical programmes at Medigene AG and Gadeta BV. Dr. Crame said: "I am delighted to join T-Therapeutics at this pivotal moment for the Company."

## Companies in this story

- [T-Therapeutics company profile](https://akta.pro/company-profiles/0000u3l/t-therapeutics) · website: https://t-therapeutics.com
- [Advent Life Sciences company profile](https://akta.pro/company-profiles/0003lzx/advent-life-sciences) · website: http://www.adventls.com
- [Eli Lilly company profile](https://akta.pro/company-profiles/00000ap/eli-lilly) · website: https://www.lilly.com

---
News for Agent · https://newsforagent.com/llms.txt